Sutro Biopharma
STRO
115 hedge funds and large institutions have $248M invested in Sutro Biopharma in 2023 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 49 increasing their positions, 30 reducing their positions, and 20 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 30
0.73% more ownership
Funds ownership: 8.58% → 9.31% (+0.73%)
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
2% less funds holding
Funds holding: 117 → 115 (-2)
38% less capital invested
Capital invested by funds: $398M → $248M (-$151M)
60% less call options, than puts
Call options by funds: $2K | Put options by funds: $5K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$7.29M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$6.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$6.8M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$3.16M |
| 5 |
Goldman Sachs
New York
|
+$2.69M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.39M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.43M |
| 3 |
Millennium Management
New York
|
-$3.03M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.91M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$2.28M |
STRO Hedge Fund Activity: Q1 2023 in Review
115 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q1 2023, worth a combined $248M — down 38% from $398M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of STRO and 19 opened new positions — a net loss of 1 holder — while 30 trimmed existing stakes and 49 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $7.29M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $6.39M sold.
- 115 institutional investors held Sutro Biopharma (STRO) as of Q1 2023, down from 117 in Q4 2022.
- Funds reported $248M of Sutro Biopharma stock for Q1 2023, down 38% quarter-over-quarter.
- 19 funds opened new Sutro Biopharma positions in Q1 2023 and 20 closed out, a net change of -1 holder.
- The largest Sutro Biopharma buyer in Q1 2023 was Rubric Capital Management (New York), an estimated $7.29M added.
- The largest Sutro Biopharma seller in Q1 2023 was Point72 Asset Management, an estimated $6.39M sold.
Based on aggregated 13F filings for Q1 2023.